Corneal Epithelial Alterations Associated With Cyclin-Dependent Kinase 4/6 Inhibitor Therapy in Hormone Receptor–Positive Breast Cancer
Importance Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are standard therapy for hormone receptor–positive (HR+), HER2-negative breast cancer. By blocking the G1/S cell-cycle transition, these agents may impair renewal of the corneal…
read more